Efficacy and Safety of JT001 (VV116) Compared With Paxlovid

COVID-19 Clinical Trial

Official title:

A Multicenter, Single-blind, Randomized, Controlled Study to Evaluate the Efficacy and Safety of JT001 (VV116) Compared With Paxlovid for the Early Treatment of COVID-19 in Participants With Mild to Moderate COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05341609
• Other study ID #: JT001-010-COVID-19
• Status: Completed
• Phase: Phase 3
• Start date: April 4, 2022
• Est. completion date: May 31, 2022

Study information

• Verified date: September 2022
• Source: Vigonvita Life Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of JT001 (VV116) Compared With Paxlovid for the Treatment of Coronavirus Disease 2019 (COVID-19) in Participants With Mild to Moderate COVID-19.

Description:

Screening Interested participants will sign the appropriate informed consent form (ICF) prior to completion of any study procedures.

The investigator will review symptoms, risk factors and other non-invasive inclusion and exclusion criteria prior to any invasive procedures.

Treatment and Assessment Period

This is the general sequence of events during the 28-day treatment and assessment period:

Complete baseline procedures Participants are randomized to an intervention group Participants receive study intervention (Q12H X 5 days), and Complete all safety monitoring

Recruitment information / eligibility

• Status: Completed
• Enrollment: 822
• Est. completion date: May 31, 2022
• Est. primary completion date: May 13, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants who have a positive SARS-CoV-2 test result.

• Participants who have one or more mild or moderate COVID-19 symptoms, and total symptom score = 2.

• Participants who have one or more of the following requirements: =7 days from the first positive test for SARS-COV-2 virus infection to the first dose; =5 days from the first onset of COVID-19 symptoms to the first dose; SARS-CoV-2 Ct Value =20 within 24 hours prior to the first dose.

• Participants who satisfy one or more than one of the following high risks for progression to severe COVID-19, including death.

• Participants who must agree to adhere to contraception restrictions.

• Participants who understand and agree to comply with planned study procedures.

• Participants or legally authorized representatives can give written informed consent approved by the Ethical Review Board governing the site.

• Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

• Participants who are judged by the investigator as likely to progress to severe/critical COVID-19 prior to randomization.

• Participants who have SpO2=93% on room air at sea level or PaO2/FiO2= 300, or respiratory rate =30 per minute.

• Participants who require mechanical ventilation or anticipated impending need for mechanical ventilation.

• Participants who have eye disease.

• Participants who have any of the following conditions when screening: ALT or AST>1.5 ULN; e GFR <60 mL/min.

• Participants who have known allergies to any of the components used in the formulation of the interventions.

• Any medical condition, which in the opinion of the Investigator, will compromise the safety of the participant.

• Participants who have received a SARS-CoV-2 monoclonal antibody treatment or prevention, or antiviral treatment (including the investigational treatment).

• Participants who have received convalescent COVID-19 plasma treatment.

• Participant's use of contraindicated drugs in the Package Insert of Nirmatrelvir Tablet/Ritonavir Tablets.

• Participants who have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed.

• Participants who are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

• Female who is pregnant or breast-feeding or plan to be pregnant within this study period.

• Male whose wife or partner plan to be pregnant within this study period.

Related Conditions & MeSH terms

• COVID-19

Intervention

Drug:
• JT001
Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days
• Paxlovid
Day 1~5: 300 mg of Nirmatrelvir and 100 mg of ritonavir, Q12H X 5 days

Locations

Country	Name	City	State
China	Huashan Hospital affiliated to Fudan University	Shanghai	Shanghai
China	Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine	Shanghai	Shanghai
China	Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine	Shanghai	Shanghai
China	Shanghai Public Health Clinical Center	Shanghai	Shanghai
China	Shanghai Pudong Hospital	Shanghai	Shanghai
China	Shanghai Tongren Hospital	Shanghai	Shanghai
China	ShuGuang Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Vigonvita Life Sciences

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to sustained clinical recovery	Time to sustained clinical recovery up to 28 days.	Up to 28 days
Secondary	AEs and SAEs through Day 28	AEs and SAEs through Day 28	Up to 28 days
Secondary	Percentage of participants who experience these events by Day 28	Percentage of participants who experience these events by Day 28; Progress to severe and/or critical COVID-19; Death from any cause	Day 1 to 28 days
Secondary	Percentage of clinical recovery participants	Percentage of clinical recovery participants from baseline to Days 3, 5, 7, 10, 14, 21 and 28	Days 3, 5, 7, 10, 14, 21 and 28
Secondary	The change of COVID-19 symptom scores	The change of "COVID-19 symptom scores" from baseline to Days 3, 5, 7, 10, 14, 21 and 28, the score ranges from 0 to 33 and higher scores mean a worse symptom.	Days 3, 5, 7, 10, 14, 21 and 28
Secondary	The change of WHO clinical progression scale	The change of "WHO clinical progression scale" from baseline to Days 3, 5, 7, 10, 14, 21 and 28, the score ranges from 0 to 10 and higher scores mean a worse clinical progression.	Days 3, 5, 7, 10, 14, 21 and 28
Secondary	Percentage of participants with SARS-CoV-2 clearance	Percentage of participants with SARS-CoV-2 clearance on Days 3, 5, 7, 10 and 14	Days 3, 5, 7, 10, 14
Secondary	The change of SARS-COV-2 Ct value	The change of SARS-COV-2 Ct value at Days 3, 5, 7, 10, 14	Days 3, 5, 7, 10, 14
Secondary	The change of Chest CT scan	The change of Chest CT scan from baseline to Days 7 or 10. The change from baseline involves not changed, getting worse, getting better as assessed by the investigator.	Days 7 or 10
Secondary	Percentage of the participants who have progression of COVID-19 though Day 28	Progress to severe and/or critical COVID-19; Death from any cause	Up to 28 days
Secondary	Percentage of participants whose "WHO clinical progression scale" reduced at least one level	Percentage of participants whose "WHO clinical progression scale" reduced at least one level from baseline to Days 3, 5, 7, 10, 14, 21 and 28. The score ranges from 0 to 10 and the higher scores mean a worse clinical progression level.	Days 3, 5, 7, 10, 14, 21 and 28
Secondary	Time to sustained clinical symptom resolution	Time to sustained clinical symptom resolution	Up to 28 days
Secondary	Percentage of participants with clinical symptom resolution	Percentage of participants with clinical symptom resolution from baseline to Days 3, 5, 7, 10, 14, 21 and 28	Days 3, 5, 7, 10, 14, 21 and 28